Prompt Reduction in Use of Medications for Comorbid Conditions After Bariatric Surgery

@article{Segal2009PromptRI,
  title={Prompt Reduction in Use of Medications for Comorbid Conditions After Bariatric Surgery},
  author={Jodi B Segal and Jeanne M Clark and Andrew D. Shore and Francesca Dominici and Thomas H. Magnuson and Thomas Richards and Jonathan P. Weiner and Eric B. Bass and Albert W. Wu and Martin A. Makary},
  journal={Obesity Surgery},
  year={2009},
  volume={19},
  pages={1646-1656}
}
BackgroundBariatric surgery leads to weight loss, but it is unclear whether surgery reduces conditions associated with obesity. We explored this by assessing the change in use of medications to treat diabetes mellitus, hypertension, and hyperlipidemia in the year following surgery.MethodsThis is a cohort study using administrative data from 2002 to 2005 from seven Blue Cross/Blue Shield Plans. We compared the mean number of medications at the time of surgery and in the subsequent year… Expand
Medication Use Following Bariatric Surgery: Factors Associated with Early Discontinuation
TLDR
Baseline co-morbidities, particularly type 2 diabetes, male sex, and Roux-en-Y gastric bypass surgery were significantly associated with decreased total medication use following surgery, and weight loss, systemic disease, sex, baseline co- Morbidity, surgical complications, and race were significant associated with continued use of specific medications following surgery. Expand
The Impact of Bariatric Surgery on Comorbidities and Medication Use Among Obese Patients
TLDR
Bariatric surgery was associated with significant reductions in reported claims for short- and long-term health outcomes and reduced medication use for major disease categories. Expand
Medication and nutritional supplement use before and after bariatric surgery.
TLDR
After bariatric surgery, there were increases in the use of vitamins, gastric antisecretory drugs and antianemic drugs and there was an overall reduction in drug use during this period, caused by suspension of drugs or dose reduction. Expand
Association of Bariatric Surgery and National Medication Use.
TLDR
A longitudinal analysis of 2007-2012 claims data comparing a bariatric surgical cohort with a propensity-matched nonsurgical control group during a 5-year time period showed total pharmacy use and costs showed a significant and sustained reduction during a 4-year follow-up period among patients undergoing gastric bypass or band operations. Expand
Influence of bariatric surgery on the use of medication
TLDR
For some major drug classes 12 months after bariatric surgery, the use of drugs decreases in terms of mean number per patient, and a reduction in dose intensity was observed for oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. Expand
Economic Impact of the c linical Benefits of Bariatric Surgery in Diabetes Patients
TLDR
Surgical therapy is clinically more effective and ultimately less expensive than standard therapy for diabetes patients with BMI ≥35 kg/m 2 and the therapeutic benefits of bariatric surgery on diabetes translate into considerable economic benefits. Expand
Medication Use Among Patients Prior to Bariatric Surgery.
TLDR
Candidates for weight loss surgery report taking medications associated with obesity-related comorbidities such as diabetes, depression, and hypertension, which may require close monitoring and dosage adjustment after surgery. Expand
The Impact of Bariatric Surgery on Thyroid Function and Medication Use in Patients with Hypothyroidism
TLDR
There is a favorable effect of BS on the hypothyroid bariatric population, which includes improvement of thyroid function and reduction of thyroid medication dosages, which is directly correlated to baseline TSH but not to BMI reduction. Expand
Clinical Factors Associated With Remission of Obesity-Related Comorbidities After Bariatric Surgery.
TLDR
The improvement in obesity-related comorbidities after bariatric surgery is estimated and clinical factors associated with these responses are identified using a large representative population of patients. Expand
Bariatric surgery is expensive but improves co-morbidity: 5-year assessment of patients with obesity and type 2 diabetes.
TLDR
Bariatric surgery in obese patients with T2DM is expensive, but leads to an improved co-morbidity profile, and reduced length of hospitalization. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Bariatric Surgery: A Systematic Review and Meta-analysis
TLDR
Effective weight loss was achieved in morbidly obese patients after undergoing bariatric surgery, and a substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement. Expand
Survival and Changes in Comorbidities After Bariatric Surgery
TLDR
Morbidly obese Medicare patients who underwent bariatric surgery had increased survival rates over the 2 years of this study when compared with a similar morbidly obese nonsurgical group, and the diagnosed prevalence of weight-related comorbid conditions declined afterbariatric surgery relative to a control cohort of morbidly obesity patients who did not undergo surgery. Expand
The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus
Of 232 morbidly obese patients with non-insulin-dependent diabetes mellitus referred to East Carolina University between March 5, 1979, and January 1, 1994, 154 had a Roux-en-Y gastric bypassExpand
Long-term changes in weight loss and obesity-related comorbidities after Roux-en-Y gastric bypass: a primary care experience.
TLDR
EWL and proportion of subjects with resolved hypertension and obstructive sleep apnea are inferior to the non-VA population, Nevertheless, improvements in measures of success are maintained in the VA population. Expand
Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass.
TLDR
Weight loss after laparoscopic gastric bypass substantially improves lipid profiles in morbidly obese patients who have hyperlipidemia, and can reduce health risks associated with high levels of atherogenic lipoproteins. Expand
Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult‐Onset Diabetes Mellitus
TLDR
The gastric bypass operation provides long-term control of non-insulin-dependent diabetes mellitus (NIDDM) and antidiabetic effects appear to be due primarily to a reduction in caloric intake, suggesting that insulin resistance is a secondary protective effect rather than the initial lesion. Expand
Long-term outcomes following laparoscopic adjustable gastric banding: Postoperative psychological sequelae predict outcome at 5-year follow-up
TLDR
Although pre-surgical psychiatric assessment alone cannot predict outcome, an absence of preoperative psychiatric illness should not reassure surgeons who should be mindful of postoperative psychiatric sequelae, particularly BED. Expand
Change in Mental Symptoms in Extreme Obesity Patients after Gastric Banding, Part II: Six-Year Follow up
TLDR
It was found that positive changes in BMI reduction, psychosocial symptoms, and health related quality of life could be expected three years after gastric banding. Expand
The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism
TLDR
Roux-en-Y gastric bypass determines considerable hormonal changes before significant BMI changes take place, and results support the hypothesis of an endocrine effect as the possible mechanism of action of RYGB. Expand
Psychosocial Functioning following Bariatric Surgery
TLDR
Although there are mixed results, the overall improvements in psychosocial functioning provide additional justification for surgical treatment of morbid obesity. Expand
...
1
2
3
...